EUVIMEDEUVIMED entdecken
Crossref

Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators’ era

Morgan Pines, Dorothy Kleinert, Charlene Thomas, Cheryl Mensah, Khaled M Musallam, Sujit Sheth

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06092-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Morgan Pines und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Iron Chelating Agents, Thalassemia, Iron Overload, Deferoxamine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Cooley’s Anemia Foundation of Maryland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron overload is a common complication in patients with transfusion-dependent-thalassemia that can lead to end-organ damage. Management of iron overload has considerably evolved since the early 2000s with the approval of oral iron chelators and widespread use of MRI monitoring. We conducted a retrospective cohort study of 144 patients with transfusion-dependent-thalassemia treated at a single center in the US and followed since initiation of regular transfusion therapy. Patients who were receiving deferoxamine monotherapy and then switched to/added an oral chelator had a mean decrease in liver iron concentration (LIC) by 0.02 mg/g dry weight (dw) per month (0.24 mg/g dw per year) and a mean increase in cardiac T2* by 0.07 ms per month (1.68 ms per year) after starting an iron chelator (p 15 mg/g dw). The introduction of oral chelators has transformed management in patients with transfusion-dependent thalassemia and led to persistent improvements in iron burden over the years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iron Chelating AgentsThalassemiaIron OverloadDeferoxamineChelation TherapyHumansMaleRetrospective StudiesFemaleAdultAdministration, OralBlood TransfusionIronMiddle AgedAdolescentLiverYoung Adult

Stichwörter der Autor:innen

DeferasiroxDeferiproneHeartIron overloadLiver

Substanzen

Iron Chelating AgentsDeferoxamineIron

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Center for Research on Rare Blood Disorders (CR-RBD), Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.

Förderung

  • Cooley’s Anemia Foundation of Maryland

Zitieren

APA

Pines, M., Kleinert, D., Thomas, C., Mensah, C., Musallam, K. M., & Sheth, S. (2024). Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators’ era. Annals of Hematology. https://doi.org/10.1007/s00277-024-06092-1

Vancouver

Pines M, Kleinert D, Thomas C, Mensah C, Musallam KM, Sheth S. Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators’ era. Annals of Hematology. 2024. doi:10.1007/s00277-024-06092-1

BibTeX
@article{Pines2024,
  author = {Pines, Morgan and Kleinert, Dorothy and Thomas, Charlene and Mensah, Cheryl and Musallam, Khaled M and Sheth, Sujit},
  title = {Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators’ era},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06092-1}
}
Kostenlos starten →